Literature DB >> 11931724

Painful Peripheral Neuropathy.

Gil I. Wolfe1, Richard J. Barohn.   

Abstract

Treatment of neuropathic pain is the primary focus of management for many patients with painful peripheral neuropathies. Neuropathic pain is a common feature of many peripheral neuropathies including those associated with diabetes, uremia, HIV infection, and alcohol abuse. Pain is also present in the majority of patients with idiopathic sensory and sensorimotor polyneuropathies. A growing number of pharmacologic agents are available for the treatment of neuropathic pain. The medications that have undergone the most rigorous study are the tricyclic antidepressants and anticonvulsants. These two families of medications are widely used and represent first-line agents in the management of neuropathic pain. Pain management should begin with a concerted effort to identify the etiology of the neuropathy, as directed therapy may help alleviate the symptoms. When initiating pharmacotherapy for neuropathic pain, one must individualize treatment and choose an agent that is likely to be tolerated, as adverse events are not uncommon for some of the medications. Treatment of neuropathic pain remains challenging, with considerable variability in an individual's response to the various agents and even to different drugs in the same class. However, monotherapy with a well-chosen agent or rational polypharmacy that combines medications with different mechanisms of action will benefit a majority of patients with neuropathic pain.

Entities:  

Year:  2002        PMID: 11931724     DOI: 10.1007/s11940-002-0034-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  9 in total

1.  Experimental muscle pain decreases the frequency threshold of electrically elicited muscle cramps.

Authors:  Mariano Serrao; Lars Arendt-Nielsen; Hong-You Ge; Francesco Pierelli; Giorgio Sandrini; Dario Farina
Journal:  Exp Brain Res       Date:  2007-06-06       Impact factor: 1.972

2.  Controlling neuropathic pain in HIV.

Authors:  Susama Verma; Lydia Estanislao; Letty Mintz; David Simpson
Journal:  Curr HIV/AIDS Rep       Date:  2004-09       Impact factor: 5.071

3.  Modulation of human immunodeficiency virus infection by anticonvulsant drugs.

Authors:  Barry Robinson; Jadwiga Turchan; Caroline Anderson; Ashok Chauhan; Avindra Nath
Journal:  J Neurovirol       Date:  2006-02       Impact factor: 2.643

4.  Controlling Neuropathic Pain in HIV.

Authors:  Susama Verma; Lydia Estanislao; Letty Mintz; David Simpson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

5.  Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups.

Authors:  Christian Martini; Ashraf Yassen; Erik Olofsen; Paul Passier; Malcom Stoker; Albert Dahan
Journal:  J Pain Res       Date:  2012-03-15       Impact factor: 3.133

6.  Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial.

Authors:  Surena Nazarbaghi; Mohammad Reza Amiri-Nikpour; Aynaz Foroughi Eghbal; Rohollah Valizadeh
Journal:  Electron Physician       Date:  2017-10-25

Review 7.  Localized neuropathic pain: an expert consensus on local treatments.

Authors:  Gisèle Pickering; Elodie Martin; Florence Tiberghien; Claire Delorme; Gérard Mick
Journal:  Drug Des Devel Ther       Date:  2017-09-13       Impact factor: 4.162

Review 8.  Topical Lidocaine for Chronic Pain Treatment.

Authors:  Marion Voute; Véronique Morel; Gisèle Pickering
Journal:  Drug Des Devel Ther       Date:  2021-09-29       Impact factor: 4.162

9.  Prevalence and clinical characteristics associated with peripheral neuropathy amongst persons on HAART in Busia County, Kenya.

Authors:  John N Mukoma; Joseph M Matheri; Nassib Tawa
Journal:  S Afr J Physiother       Date:  2020-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.